-
How to develop a universal vaccine that beats COVID, SARS, MERS and the common cold!
Time of Update: 2020-07-28
"New Year's Day " - The virus that causes it belongs to a family of coronaviruses that can cause everything from the common cold to MERS, which kills about one-third of those infected Although these
-
Psoriasis Phase III Clinical: Lilly's IL-23 Monoantimizumab is better than Novartis's IL-17A Monotstyx.
Time of Update: 2020-07-28
Lilly incision () monoantitherapy patients with primary to severe plaque-like psoriasis showed that the drug reached all major and major secondary endpoints in the first week compared to a placebo And
-
NEJM: PRIME cells with rheumatoid arthritis attacks.
Time of Update: 2020-07-28
Rheumatoid arthritis, like many inflammatory diseases, has a period of rest and deterioration (flare) but the mechanism that causes the flare is not clear Recently, researchers established a clinical
-
The global research community requires the correct research of COVID-19 in the right place.
Time of Update: 2020-07-28
NEW YEAR-OLD - A report has been released calling for the use of research evidence on the best implementation of public health interventions in different global settings In the absence of vaccines and
-
Clin Cancer Res: Scientists have identified new potential targets for immunotherapy for melanoma.
Time of Update: 2020-07-28
A recent study published in the International Journal of the Institute of Medicine and other scientists through a study revealed why some melanoma patients do not respond to immunotherapy related find
-
First lupus nephritis (LN) drug! The new best-in-class calcium-modulating neurophosphatase inhibitor voclosporin has been reviewed by the FDA!
Time of Update: 2020-07-28
New Year's Day is a biopharmaceutical company dedicated to the development of innovative therapies for kidney disease and autoimmune diseases The company recently announced that the U.S Food and Drug
-
New achievements made by scientists in the field of organ transplantation!
Time of Update: 2020-07-28
"This article collates the recent achievements made by scientists in the field of organ transplantation research to learn with you! FILE Photo: A new technology has been developed that can significan
-
NEJM: Local therapy of loferst cream can significantly improve skin symptoms in psoriasis patients.
Time of Update: 2020-07-28
Oral systemic phosphodiesterase inhibitors have a better efficacy in the treatment of psoriasis Recently researchers assessed the effectiveness of local treatment of psoriasis in Loforstette cream Adu
-
Several articles focus on important research results in the field of atherosclerosis research!
Time of Update: 2020-07-28
"This article has compiled a number of important research results to focus on recent advances in the field of atherosclerosis research to share with you! FILE Photo: Revealing the relationship betwee
-
Systemic sclerosis-related interstitial pulmonary disease patients, how to turn the risk of "dimensional" yi?
Time of Update: 2020-07-28
the results showed that compared with placebo, nidanib significantly reduced the annual decline rate of FVC in SSc ILD patients and delayed disease progression.
-
Science: Uncovering how metastatic cancer keeps moving in an unfavourable cobweb subcavity environment?
Time of Update: 2020-07-28
In a recent study published in the international journal, scientists from institutions such as memorial Sloan Kettering Cancer Center have revealed how metastatic cancer survives in an adverse cobweb
-
Several important research results focus on new advances in microRNA molecular research!
Time of Update: 2020-07-28
"This article has compiled a number of important research results to focus on scientists in the field of molecular research and new progress to share with you! Photo Source: : New Breakthrough! Scien
-
The interleukin-1 blocker Rilonacept treats operitis and is awarded the title of orphan drug by the FDA.
Time of Update: 2020-07-28
The company announced that the treatment of encephalomyelitis, including recurrent encephalitis, has been awarded the title of Orphan Drug by the U.S Food and Drug Administration () Recombinant fusio
-
A new drug for adhesion dermatitis (AD) ! AbbVie oral JAK inhibitor Rinvoq single drug treatment of severe AD Phase II PHASE III STUDY WAS SUCCESSFUL!
Time of Update: 2020-07-28
AbbVie () recently announced that the evaluation of oral inhibitors () single drug therapy for aspecific dermatitis () phase II clinical study ( ) has reached the primary and all secondary endpoints T
-
Science: Three different immune responses were revealed in patients with more severe COVID-19.
Time of Update: 2020-07-28
In a new study, researchers at the Perelman School of Medicine at the University of Pennsylvania found that three different immune responses to infections may help predict the trajectory of disease i
-
Nature's big break! Create a complete sequence of human X chromosomes!
Time of Update: 2020-07-28
Researchers at the National Human Genome Institute, part of the National Institutes of Health, created the first end-to-end sequence of human chromosomes The results, published recently in the journa
-
Arthritis pain "death to live", these methods are too useful! Guide time.
Time of Update: 2020-07-28
the guidelines for non-surgical treatment of osteoarthritis published by OARSI in 2019 strongly recommend topical NSAIDs for patients with knee OA, especially for patients with gastrointestinal and / or cardiovascular diseases, as well as elderly and frail patients.
-
Ann Rheum Dis: Tumor necrosis factor inhibitors can slow the imaging progress of aggressive spina bifida.
Time of Update: 2020-07-28
Tumor necrosis factor inhibitors () have been shown to slow the imaging progress of aggressive spina bifida However, the limitation factors such as changes in disease activity, complex drug management
-
Ann Rheum Dis: Severe new crown pneumonia inflammatory storm sarilumab uses sarilumab to block the efficacy of interleukin-6.
Time of Update: 2020-07-28
The study was designed to assess the safety and efficacy of using blocking interleukin in patients with severe neo-coronary pneumonia associated with systemic inflammatory storms An open label study
-
Redseywe's good news again! Phase III clinical lying is effective in patients with COVID-19!
Time of Update: 2020-07-28
MATH ( UPI) -- The latest clinical trial results from Gilead, the maker of the antiviral drug Redseve, show more good news for the drug's efficacy Gilead said recently that in a trial involving multip